Gordon Graham

628 total citations
24 papers, 428 citations indexed

About

Gordon Graham is a scholar working on Statistics and Probability, Management Science and Operations Research and Computational Theory and Mathematics. According to data from OpenAlex, Gordon Graham has authored 24 papers receiving a total of 428 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Statistics and Probability, 9 papers in Management Science and Operations Research and 3 papers in Computational Theory and Mathematics. Recurrent topics in Gordon Graham's work include Statistical Methods in Clinical Trials (12 papers), Optimal Experimental Design Methods (9 papers) and Statistical Methods and Bayesian Inference (5 papers). Gordon Graham is often cited by papers focused on Statistical Methods in Clinical Trials (12 papers), Optimal Experimental Design Methods (9 papers) and Statistical Methods and Bayesian Inference (5 papers). Gordon Graham collaborates with scholars based in United Kingdom, Switzerland and United States. Gordon Graham's co-authors include Leon Aarons, Kayode Ogungbenro, Ivelina Gueorguieva, David J. Lunn, David J. Spiegelhalter, Beat Neuenschwander, Nicky Best, Elsa Valdés‐Márquez, John Whitehead and Patrick Johnson and has published in prestigious journals such as PLoS ONE, Neurology and Statistics in Medicine.

In The Last Decade

Gordon Graham

22 papers receiving 411 citations

Peers

Countries citing papers authored by Gordon Graham

Since Specialization

Citations

This map shows the geographic impact of Gordon Graham's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gordon Graham with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gordon Graham more than expected).

Fields of papers citing papers by Gordon Graham

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gordon Graham. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gordon Graham. The network helps show where Gordon Graham may publish in the future.

Co-authorship network of co-authors of Gordon Graham

This figure shows the co-authorship network connecting the top 25 collaborators of Gordon Graham. A scholar is included among the top collaborators of Gordon Graham based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gordon Graham. Gordon Graham is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Prognostic factors for worsening and improvement in multiple sclerosis using a multistate model 2024 ·Multiple Sclerosis Journal ·Alex Ocampo, (unknown), Jelena Čuklina, Gordon Graham, Habib Ganjgahi, (unknown), Wendy Su, (unknown), (unknown), (unknown), (unknown), Bernd C. Kieseier, Douglas L. Arnold, Robert A Bermel, Dieter A. Häring, Thomas E. Nichols, Heinz Wiendl	0
2	A scalable approach for continuous time Markov models with covariates 2023 ·Biostatistics ·(unknown), Alex Ocampo, Gordon Graham, Thomas E. Nichols, Habib Ganjgahi	0
3	The Development of Ofatumumab, a Fully Human Anti-CD20 Monoclonal Antibody for Practical Use in Relapsing Multiple Sclerosis Treatment 2023 ·Neurology and Therapy ·Stephen L. Hauser, Ludwig Kappos, Amit Bar‐Or, Heinz Wiendl, David Paling, Mitzi Williams, Ralf Gold, Andrew Chan, Ron Milo, Ayan Das Gupta, Goeril Karlsson, (unknown), Gordon Graham, Martin Merschhemke, Dieter A. Häring, Patrick Vermersch	17
4	Rationale for Use of Sphingosine-1-Phosphate Receptor Modulators in COVID-19 Patients: Overview of Scientific Evidence 2022 ·Journal of Interferon & Cytokine Research ·Thomas Hach, Kasra Shakeri‐Nejad, Marc Bigaud, Frank Dahlke, (unknown), Olivier Pétricoul, Gordon Graham, (unknown), (unknown), Volker Brinkmann, Ferdinando Nicoletti	6
5	Population Pharmacokinetic–B Cell Modeling for Ofatumumab in Patients with Relapsing Multiple Sclerosis 2022 ·CNS Drugs ·Huixin Yu, Gordon Graham, Olivier J. David, Joseph M. Kahn, (unknown), Etienne Pigeolet, Ayan Das Gupta, Ratnakar Pingili, Roman Willi, Prakash Krishnan, Bernd C. Kieseier, Dieter A. Häring, Morten Bagger, Per Soelberg Sørensen	24
6	Comparable Ofatumumab Treatment Outcomes in Patients across Racial/Ethnic Groups in the ASCLEPIOS I/II and APOLITOS studies (4139) 2021 ·Neurology ·Silvia Delgado, Mitzi Williams, Morten Bagger, Gordon Graham, Etienne Pigeolet, Huixin Yu, Dieter Haering, Roman Willi, Cécile Kerloëguen, Chao Xu, Masaru Hirano, (unknown), Wendy Su, Prakash Krishnan, Jin Nakahara	2
7	Mammals of Australia's Tropical Savannas: A Conceptual Model of Assemblage Structure and Regulatory Factors in the Kimberley Region 2014 ·PLoS ONE ·Ian J. Radford, Chris R. Dickman, (unknown), Carol Palmer, (unknown), (unknown), (unknown), Gordon Graham, (unknown), (unknown)	32
8	Evaluation of the Pre-Posterior Distribution of Optimized Sampling Times for the Design of Pharmacokinetic Studies 2011 ·Journal of Biopharmaceutical Statistics ·Stephen B. Duffull, Gordon Graham, Kerrie Mengersen, J. A. Eccleston	8
9	Combining MCMC with ‘sequential’ PKPD modelling 2009 ·Journal of Pharmacokinetics and Pharmacodynamics ·David J. Lunn, Nicky Best, David J. Spiegelhalter, Gordon Graham, Beat Neuenschwander	63
10	Population pharmacokinetics and optimal design of paediatric studies for famciclovir 2009 ·British Journal of Clinical Pharmacology ·Kayode Ogungbenro, (unknown), Michael Looby, (unknown), Gordon Graham, Leon Aarons	21
11	A program for individual and population optimal design for univariate and multivariate response pharmacokinetic–pharmacodynamic models 2007 ·Computer Methods and Programs in Biomedicine ·Ivelina Gueorguieva, Kayode Ogungbenro, Gordon Graham, Sophie Glatt, Leon Aarons	45
12	Bayesian sample size for exploratory clinical trials incorporating historical data 2007 ·Statistics in Medicine ·John Whitehead, Elsa Valdés‐Márquez, Patrick Johnson, Gordon Graham	36
13	Optimal Design for Multiresponse Pharmacokinetic–Pharmacodynamic Models – Dealing with Unbalanced Designs 2007 ·Journal of Pharmacokinetics and Pharmacodynamics ·Kayode Ogungbenro, Ivelina Gueorguieva, Oneeb Majid, Gordon Graham, Leon Aarons	18
14	Optimum blood sampling time windows for parameter estimation in population pharmacokinetic experiments 2006 ·Statistics in Medicine ·Gordon Graham, Leon Aarons	25
15	The use of a modified Fedorov exchange algorithm to optimise sampling times for population pharmacokinetic experiments 2005 ·Computer Methods and Programs in Biomedicine ·Kayode Ogungbenro, Gordon Graham, Ivelina Gueorguieva, Leon Aarons	27
16	A program for the optimum design of pharmacokinetic, pharmacodynamic, drug metabolism and drug–drug interaction models 2005 ·Computer Methods and Programs in Biomedicine ·Gordon Graham, Ivelina Gueorguieva, (unknown)	6
17	Determination of an Optimal Dosage Regimen Using a Bayesian Decision Analysis of Efficacy and Adverse Effect Data 2002 ·Journal of Pharmacokinetics and Pharmacodynamics ·Gordon Graham, Suneel Gupta, Leon Aarons	17
18	Modeling and Simulation for Clinical Trial Design Involving a Categorical Response: A Phase II Case Study with Naratriptan 2001 ·Pharmaceutical Research ·Ivan Nestorov, Gordon Graham, Stephen B. Duffull, Leon Aarons, Eliane Fuseau, Peter E. Coates	27
19	Methodological approaches to the population analysis of toxicity data 2001 ·Toxicology Letters ·Leon Aarons, Gordon Graham	10
20	The Justice of intervention 1987 ·Review of International Studies ·Gordon Graham	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact